AtonRa Partners Sells 273 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AtonRa Partners decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.3% during the 4th quarter, HoldingsChannel reports. The firm owned 2,662 shares of the biopharmaceutical company’s stock after selling 273 shares during the quarter. AtonRa Partners’ holdings in Alnylam Pharmaceuticals were worth $510,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Quent Capital LLC boosted its stake in Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. Anchor Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $38,000. GAMMA Investing LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $52,000. Lindbrook Capital LLC grew its holdings in shares of Alnylam Pharmaceuticals by 37.2% during the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 100 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in Alnylam Pharmaceuticals by 52.4% during the 3rd quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 311 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on ALNY shares. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. HC Wainwright restated a “buy” rating and set a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. BMO Capital Markets restated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, February 1st. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $215.88.

Alnylam Pharmaceuticals Stock Up 2.8 %

Alnylam Pharmaceuticals stock traded up $4.05 during trading hours on Monday, reaching $147.36. 439,847 shares of the company’s stock were exchanged, compared to its average volume of 772,379. The firm’s 50 day simple moving average is $150.21 and its 200 day simple moving average is $165.76. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $218.88. The firm has a market capitalization of $18.56 billion, a PE ratio of -41.17 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million for the quarter, compared to the consensus estimate of $439.38 million. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.68) EPS. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.46 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.